Eddingpharm Buys China Marketing Rights For GSK Breast-Cancer Drug
This article was originally published in PharmAsia News
China's Eddingpharm drug marketer has bought the local rights for GlaxoSmithKline's recently approved Tykerb (lapatinib) for treating metastatic breast cancer.
You may also be interested in...
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
Smiths Medical is increasing paraPAC ventilator production from hundreds to thousands a month to fulfill 10,000 units as part of the Ventilator Challenge UK consortium.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.